The FDA has accepted a biologics license application for Blenrep plus bortezomib or pomalidomide for patients with relapsed ...

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug had reached statistical ...

Berenberg lowered the firm’s price target on GSK (GSK) to 1,600 GBp from 1,820 GBp and keeps a Buy rating on the shares.Don't Miss our Black ...

The FDA granted approval to nilotinib (Danziten) on November 14, 2024, for the treatment of adult patients with newly ...

One of the major stories in multiple myeloma in 2024 was the comeback of belantamab mafodotin (Blenrep) after it had been ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for Blenrep (belantamab mafodotin) in combinations with bortezomib ...

“强大的创新管线布局和行动力，都让我看到了GSK对中国市场的重视和未来发展的潜力。”作为一名生物医药领域的资深从业者，张宁于2024年加入GSK中国管理团队，成为公司特药业务部负责人，他的选择正是基于对公司战略布局的认同和对未来发展的期待。

The move drew immediate opposition from politicians, including the leader of his own conservative party, Han Dong-hoon, who called the decision "wrong" and vowed to "stop it with the people."… ...

Teva Pharmaceutical Industries Ltd. ADR 0.42% $18.65B ...

32 years ago today, engineers at the Sema Group used the Vodaphone network and a computer to send the world's first SMS. It revolutionized ...

(Alliance News) - GSK PLC said on Monday that the US Food & Drug Administration accepted a biologics license application for its Blenrep combinations for the treatment of relapsed and refractory ...